Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Фаза 3 Идёт, набор закрыт NCT01892722

Кратко

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

Frequency of Relapses in Patients Treated for up to 24 Months

24 months · Confirmed relapse per year

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
• A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche

Все исследования